A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function

Mise à jour : Il y a 4 ans
Référence : NCT00641082

Femme et Homme

Extrait

A double-blind randomized, parallel, multicenter with 48 weeks of treatment period. The purpose of this study is to compare the safety and antiviral activity of 48-week Clevudine and Adefovir dipivoxil in HBeAg(-) Chronic Hepatitis B with compensated liver function.


Critère d'inclusion

  • HBeAg(-) Chronic Hepatitis B With Compensated Liver Function

Liens